Not Signed In -
Healthy People 2000 |
|
|
Clinical Trial: Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors
This study is currently recruiting patients.
|
Purpose
The purpose of this study is to clinically evaluate the spleen during PBPC mobilization by filgrastim.
| Condition | Intervention | Phase |
|---|---|---|
| Healthy | Drug: filgrastim | Phase II |
MedlinePlus consumer health information
Study Type: Observational
Study Design: Screening, Longitudinal, Defined Population, Prospective Study
Further Study Details:
Study start: November 2003
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Eligible to be PBPC donor for allogeneic transplantation as determined by local institution
Exclusion Criteria:
- History of splenectomy
- Previous PBPC mobilization attempts
- Previous treatment with GCSF or GMCSF
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00115128
Amgen Call Center 866-572-6436 mit@amgen.com
Massachusetts
Research Center, Boston, Massachusetts, United States; Recruiting
Missouri
Research Center, St. Louis, Missouri, United States; Recruiting
Wisconsin
Research Center, Wauwatosa, Wisconsin, United States; Recruiting
More Information
AmgenTrials clinical trials website
Center Watch Clinical Trials Listing Service
Study ID Numbers: 20020143
Record last reviewed: June 2005
Last Updated: June 30, 2005
Record first received: June 21, 2005
ClinicalTrials.gov Identifier: NCT00115128
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-07-05
Record last reviewed: June 2005
Last Updated: June 30, 2005
Record first received: June 21, 2005
ClinicalTrials.gov Identifier: NCT00115128
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-07-05
email this page
print this page
bookmark this page
feedback on this page
